VivoSeq
Other

First-Line

0

Pipeline Programs↗

11

Active Trials↗

3

Companies Involved↗

First-line is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, EMD Serono Research & Development Institute, Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalEMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed8 · 33%
Active, not recruiting4 · 17%
Unknown status4 · 17%
Not yet recruiting3 · 13%
Recruiting3 · 13%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

24 trials

Good-first: B/F/TAF As First-line ART
Recruiting·—·N/A·NCT06619288·630 enrolled
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT07428707·30 enrolled
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Recruiting·FFudan University·Phase 2·NCT06313970·58 enrolled
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT06894511·7 enrolled
Plasma-Adapted First-Line Pembro In NSCLC
Active, not recruiting·—·Phase 2·NCT04166487·40 enrolled
A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
Active, not recruiting·—·Phase 3·NCT05924438·600 enrolled
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Active, not recruiting·FFudan University·Phase 2·NCT06020066·202 enrolled
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07012980·38 enrolled
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
Not yet recruiting·FFudan University·Phase 2·NCT06665087·110 enrolled
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
Enrolling by invitation·NNational Cheng-Kung University Hospital·Phase 4·NCT04527055·312 enrolled
Avelumab in First-line NSCLC (JAVELIN Lung 100)
Completed·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled
Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication
Completed·NNational Taiwan University Hospital·Phase 4·NCT03897244·603 enrolled
DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV
Completed·—·Phase 3·NCT04433780·133 enrolled
Ziconotide as First-Line IDT
Completed·—·Phase 4·NCT03321955·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)